PVSRIPO for Patients With Unresectable Melanoma
A Phase I Trial of PVSRIPO for Patients With Unresectable Melanoma
調査の概要
詳細な説明
The Primary Objective of the study is to determine the safety profile of PVSRIPO in Stage IIIB, IIIC, and IV recurrent melanoma patients as determined by DLTs by cohort, as well as in those retreated with PVSRIPO, when PVSRIPO is injected intralesionally into 1 to 3 or more cutaneous or subcutaneous lesions. As planned, up to 18 patients may be treated with PVSRIPO.
Biopsy material will be obtained from tumor tissue prior to and following virus administration, which may be subjected to routine histology along with molecular genetic testing and evaluation of pathological response. Whole blood for immunologic analyses will also be collected throughout the study period.
Routine study visits will occur through Day 126. Thereafter, visits will occur every 2-3 months for up to 2 years for subjects who do not progress. For patients with progressive disease, chart review only will occur every 3 months starting at the time of progression.
Patients who previously participated in Cohorts 0 through 3, who in the opinion of the investigator, may benefit from continued PVSRIPO administration, may be eligible to receive additional injections.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
North Carolina
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Undergone prior vaccination against PV and received a boost immunization with trivalent IPOL® (Sanofi-Pasteur SA) at least 1 week, but less than 6 weeks, prior to administration of PVSRIPO (within 6 months of PVSRIPO retreatment).
a. Note: Patients who are unsure of their prior vaccination status/who have not been vaccinated must provide proof of vaccination and/or evidence of anti-PV immunity prior to enrollment, as applicable.
- The patient must have received a boost immunization with trivalent inactivated IPOL™ (Sanofi-Pasteur) at least 1 week prior to administration of the study agent.
- Patient must have histologically proven unresectable, recurrent, melanoma, stage IIIB, IIIC, or stage IV (AJCC staging must be documented in patient's medical record, as determined by CT of the chest, abdomen and pelvis, and/or whole body PET scan, and MRI of the brain within 4 weeks prior to administration of study drug).
- Patients with BRAF mutations, must have failed at least 2 lines of therapy, specifically one BRAF targeted therapy and at least one anti-PD-1 based therapy. For BRAF wild type, patients must have failed at least one anti-PD-1 based therapy.
- Patient must be ≥ 18 years of age.
- Patient must have an ECOG/Zubrod status of 0-1.
- Patient's disease must be bi-dimensionally measurable by caliper or radiological method as defined in the irRC criteria.
At least 1 injectable cutaneous, subcutaneous or nodal melanoma lesion ≥ 10 mm in longest diameter or, multiple injectable melanoma lesions which in aggregate have a longest diameter of ≥ 10 mm (Cohorts 0 and possibly 1). For cohorts where 2 or 3 injections are planned (Cohorts 1 and 2), the patient must have at least 2 injectable melanoma lesions (when 2 doses are planned) or ≥3 injectable melanoma lesions when at least 3 doses are planned in different lesions (Cohorts 2 through 4).
a. Note: PVSRIPO retreatment requires ≥2 lesions amenable to injection.
- At least one measurable lesion that will not be injected.
- Serum lactate dehydrogenase (LDH) levels less than 1.5 x upper limit of normal (ULN).
Patient must have adequate bone marrow, liver and renal function as assessed by the following:
- Hemoglobin > 9.0 g/dl
- White blood count (WBC) of > 2000 m3
- Absolute neutrophil count (ANC) > 1,000/mm3
- Platelet count > 75,000/mm3
- Total bilirubin < 2.0 x ULN
- ALT and AST < 2.5 x the ULN
Exclusion Criteria:
- Females who are pregnant or breast-feeding.
- Adults of reproductive potential not employing an effective method of birth control.
Patients with severe, active co-morbidity, defined as follows:
- Patients with an active infection requiring treatment or having an unexplained febrile illness (Tmax > 99.5°F/37.5°C).
- Patients with impaired cardiac function or clinically significant cardiac disease, such as congestive heart failure requiring treatment (New York Heart Association Class ≥ 2), uncontrolled hypertension or clinically significant arrhythmia; QTcF > 470 msec on ECG if performed or congenital long QT syndrome; acute myocardial infarction or unstable angina pectoris < 3 months prior to study.
- Patients with known lung (FEV1 < 50%) disease or uncontrolled diabetes mellitus (HgbA1c>7).
- Patients with albumin allergy.
- Autoimmune disease: History of or current active autoimmune diseases, [e.g. including but not limited to inflammatory bowel diseases [IBD], rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies (such as Guillain-Barre syndrome)]. Vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism are not exclusionary.
- Known immunosuppressive disease, human immunodeficiency virus (HIV) infection, or chronic Hepatitis B or C.
- Patients with a previous history of neurological complications due to PV infection.
- Patients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy. Guidelines for this recovery period are dependent upon the specific therapeutic agent being used. Toxicities must have resolved to CTCAE grade 1 or less with the following exceptions (alopecia, fatigue, vitiligo).
- Patients with undetectable anti-tetanus toxoid IgG.
- Patients with known history of agammaglobulinemia.
- Patients on greater than 10 mg per day of prednisone within the 2 weeks prior to admission for PVSRIPO injection.
- Patients with worsening steroid myopathy (history of gradual progression of bilateral proximal muscle weakness, and atrophy of proximal muscle groups).
- Patients with prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin.
- Clinically active cerebral or bone metastases.
- Greater than 3 visceral metastases (this does not include nodal metastases associated with visceral organs).
- Prior allogeneic stem cell transplantation.
- Concomitant therapy with any of the following: IL-2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses). However, during the course of the study, use of corticosteroids is allowed if used for treating irAEs, adrenal insufficiencies, or if administered at doses of prednisone 10 mg daily or equivalent.
- Active clinically serious infection > CTCAE Grade 2.
- Antineoplastic therapy, radiotherapy, or any other investigational drug within 15 days prior to first study drug administration.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Cohort 0 (PVSRIPO)
A single dose of PVSRIPO into a single lesion.
|
Intralesional injection of PVSRIPO.
|
実験的:Cohort 1 (PVSRIPO)
A single dose of PVSRIPO into 2 different lesions, 21 days apart, when applicable per dose escalation guidelines.
|
Intralesional injection of PVSRIPO.
|
実験的:Cohort 2 (PVSRIPO)
A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
|
Intralesional injection of PVSRIPO.
|
実験的:Cohort 3 (PVSRIPO)
A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
|
Intralesional injection of PVSRIPO.
|
実験的:Cohort 4 (PVSRIPO)
A single dose of PVSRIPO into a single lesion, followed by PVSRIPO injected into up to 6 lesions at Day 10 and every 21 days thereafter.
|
Intralesional injection of PVSRIPO.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Proportion of patients with DLTs by cohort
時間枠:24 months
|
To characterize the safety and tolerability of PVSRIPO in AJCC Stage IIIB, IIIC, or IV melanoma.
|
24 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Response rates via measurement of cutaneous lesions every 3 weeks
時間枠:24 months
|
To describe the response rates via lesion size of PVSRIPO-injected versus non-injected lesion(s).
|
24 months
|
Number of CD8 positive T cells by IHC on pre treatment and post treatment biopsy (Cohorts 0-3 only)
時間枠:4.1 months
|
To describe the number of CD8 positive T cells present in the tumor biopsies before and after injection of PVSRIPO.
|
4.1 months
|
The change in tumor pathology from baseline to after PVSRIPO injection
時間枠:4.1 months
|
Determine the pathologic response in tumor biopsies after PVSRIPO by confirming presence or absence of viable tumor cells.
|
4.1 months
|
The detection of viral replication in injected versus non injected lesions (Cohorts 0-3 only)
時間枠:4.1 months
|
Determine viral replication via a number of methods (e.g., qRT-PCR, ICH).
|
4.1 months
|
The change in inflammatory cells and markers after PVSRIPO in injected versus non injected lesions (Cohorts 0-3 only)
時間枠:4.1 months
|
Determine changes in the tumor microenvironment from biopsies after PVSRIPO; includes but not limited to examination of CD8, PVR (CD155), PD-L1, CD4, FoxPE, and PD-1.
|
4.1 months
|
Change relative to baseline in type and/or function of T cells via flow cytometry (Cohorts 0-3 only)
時間枠:24 months
|
Describe how systemic immune cell populations may change after treatment with PVSRIPO.
|
24 months
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Beasley GM, Brown MC, Farrow NE, Landa K, Al-Rohil RN, Selim MA, Therien AD, Jung SH, Gao J, Boczkowski D, Holl EK, Salama AKS, Bigner DD, Gromeier M, Nair SK. Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. J Immunother Cancer. 2022 Sep;10(9):e005052. doi: 10.1136/jitc-2022-005052.
- Beasley GM, Nair SK, Farrow NE, Landa K, Selim MA, Wiggs CA, Jung SH, Bigner DD, True Kelly A, Gromeier M, Salama AK. Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. J Immunother Cancer. 2021 Apr;9(4):e002203. doi: 10.1136/jitc-2020-002203.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
PVSRIPOの臨床試験
-
Istari Oncology, Inc.United States Department of Defense; Duke University完了
-
Darell BignerGenentech, Inc.; Istari Oncology, Inc.引きこもった
-
Istari Oncology, Inc.Duke University; Solving Kids' Cancer; The Andrew McDonough B+ Foundation完了膠芽腫 | 悪性神経膠腫 | 膠肉腫 | 上衣腫 | 髄芽腫 | 未分化乏星細胞腫 | 退形成性星細胞腫 | 未分化乏突起膠腫 | 脳の非定型奇形腫様/ラブドイド腫瘍 | 脳の多形性黄色星細胞腫 | 脳の胚性腫瘍アメリカ
-
Istari Oncology, Inc.National Cancer Institute (NCI); Duke University; Brain Tumor Research Charity Grant完了
-
Darell BignerBristol-Myers Squibb; Duke University; Istari Oncology, Inc.引きこもった